Dieter Hörsch

9.6k total citations · 4 hit papers
96 papers, 7.0k citations indexed

About

Dieter Hörsch is a scholar working on Epidemiology, Oncology and Neurology. According to data from OpenAlex, Dieter Hörsch has authored 96 papers receiving a total of 7.0k indexed citations (citations by other indexed papers that have themselves been cited), including 75 papers in Epidemiology, 53 papers in Oncology and 50 papers in Neurology. Recurrent topics in Dieter Hörsch's work include Neuroendocrine Tumor Research Advances (75 papers), Neuroblastoma Research and Treatments (49 papers) and Lung Cancer Research Studies (41 papers). Dieter Hörsch is often cited by papers focused on Neuroendocrine Tumor Research Advances (75 papers), Neuroblastoma Research and Treatments (49 papers) and Lung Cancer Research Studies (41 papers). Dieter Hörsch collaborates with scholars based in Germany, United States and United Kingdom. Dieter Hörsch's co-authors include Eric Van Cutsem, Richard P. Baum, Jonathon N. Winnay, Laurie J. Goodyear, Domenico Accili, Tatsuya Hayashi, C. Ronald Kahn, Jens C. Brüning, Juan W. Valle and Catherine Lombard‐Bohas and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Biological Chemistry.

In The Last Decade

Dieter Hörsch

94 papers receiving 6.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors

2011 1.8k citations Catherine Lombard‐Bohas, Juan W. Valle et al. profile →
A Muscle-Specific Insulin Receptor Knockout Exhibits Features of the Metabolic Syndrome of NIDDM without Altering Glucose Tolerance

1998 939 citations Dieter Hörsch et al. profile →
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

2011 767 citations Marianne Pavel, Éric Baudin et al. profile →
The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours

2013 563 citations John J. Zaknun, Richard P. Baum et al. profile →

Peers

Countries citing papers authored by Dieter Hörsch

Since Specialization

Citations

This map shows the geographic impact of Dieter Hörsch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dieter Hörsch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dieter Hörsch more than expected).

Fields of papers citing papers by Dieter Hörsch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dieter Hörsch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dieter Hörsch. The network helps show where Dieter Hörsch may publish in the future.

Co-authorship network of co-authors of Dieter Hörsch

This figure shows the co-authorship network connecting the top 25 collaborators of Dieter Hörsch. A scholar is included among the top collaborators of Dieter Hörsch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dieter Hörsch. Dieter Hörsch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	1146MO Interim analysis of CABONEN: A multicenter phase II trial investigating cabozantinib in patients with advanced, low proliferative NEN G3 2024 ·Annals of Oncology ·Alexander Köenig, James B. Reinecke, (unknown), Kristina Lång, (unknown), (unknown), Nicole Kirchhof, (unknown), Dieter Hörsch, (unknown), Michael Quante, Volker Ellenrieder, (unknown), Thomas Wirth, Alexander Weich, Leonidas Apostolidis, (unknown), Anja Rinke, Marianne Pavel	1
2	Combined Lanreotide Autogel and Temozolomide Treatment of Progressive Pancreatic and Intestinal Neuroendocrine Tumors: The Phase II SONNET Study 2024 ·The Oncologist ·Marianne Pavel, Harald Lahner, Dieter Hörsch, Anja Rinke, Timm Denecke, (unknown), (unknown), (unknown), (unknown), Markus Raderer	4
3	ENETS standardized (synoptic) reporting for neuroendocrine tumour pathology 2022 ·Journal of Neuroendocrinology ·Marie‐Louise F. van Velthuysen, Anne Couvelard, Guido Rindi, Nicola Fazio, Dieter Hörsch, Els J. Nieveen van Dijkum, Günter Klöppel, Aurel Perren	15
4	Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆ 2021 ·Annals of Oncology ·Éric Baudin, Martyn Caplin, Rocio García‐Carbonero, Nicola Fazio, Piero Ferollà, Pier Luigi Filosso, Andrea Frilling, Wouter W. de Herder, Dieter Hörsch, Ulrich Knigge, Catharina M. Korse, Eric Lim, Catherine Lombard‐Bohas, Marianne Pavel, Jean‐Yves Scoazec, Anders Sundin, Alfredo Berruti	139
5	Clinical Features and Prognosis of Patients with Carcinoid Syndrome and Carcinoid Heart Disease: A Retrospective Multicentric Study of 276 Patients 2021 ·Neuroendocrinology ·(unknown), (unknown), Anja Rinke, Thomas M. Gress, Jörg Schrader, Richard P. Baum, Daniel Kaemmerer, Dieter Hörsch	13
6	Localization Defines Streptozotocin/5-FU Response in Primary Pancreatic Neuroendocrine Tumours 2021 ·Neuroendocrinology ·(unknown), Uli Fehrenbach, Antonin Kayser, Ulrich‐Frank Pape, Frank Oliver Henes, Birgit Cremer, Dieter Hörsch, Jakob R. Izbicki, Ansgar W. Lohse, Anja Rinke, Jörg Schrader	3
7	Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Phase III Studies in Carcinoid Syndrome 2020 ·Journal of Gastrointestinal Cancer ·Joseph S. Dillon, Matthew H. Kulke, Dieter Hörsch, Lowell Anthony, Richard R.P. Warner, Emily K. Bergsland, Staffan Welin, Thomas M. O’Dorisio, Pamela L. Kunz, Chad M. McKee, Pablo Lapuerta, Phillip Banks, Marianne Pavel	7
8	Efficacy and Safety of Telotristat Ethyl in Patients With Carcinoid Syndrome Inadequately Controlled by Somatostatin Analogs : Analysis of the Completed TELESTAR Extension Period 2018 ·Pancreas ·Martin O. Weickert, Gregory Kaltsas, Dieter Hörsch, Pablo Lapuerta, Marianne Pavel, Juan W. Valle, Martyn Caplin, Emily K. Bergsland, Pamela L. Kunz, Lowell Anthony, Enrique Grande, Kjell Öberg, Staffan Welin, Richard R.P. Warner, Catherine Lombard‐Bohas, (unknown), (unknown), (unknown), Qi Yang, Matthew H. Kulke	2
9	Time to Sustained Improvement in Bowel Movement Frequency With Telotristat Ethyl : Analysis of the Phase 3 TELESTAR Study 2018 ·Pancreas ·Joseph S. Dillon, Matthew H. Kulke, Marianne Pavel, Dieter Hörsch, Lowell Anthony, Richard R.P. Warner, Emily K. Bergsland, Staffan Welin, Thomas M. O’Dorisio, Nilay Patel, Pablo Lapuerta	2
10	Unmet Needs in Appendiceal Neuroendocrine Neoplasms 2018 ·Neuroendocrinology ·Christos Toumpanakis, Nicola Fazio, Eva Tiensuu Janson, Dieter Hörsch, Andreas Pascher, Nicholas S. Reed, Dermot O’Toole, Els Nieveen van Dijkum, Stefano Partelli, Anja Rinke, Beata Kos‐Kudła, Frederico Costa, Ulrich‐Frank Pape, Simona Grozinsky‐Glasberg, Jean‐Yves Scoazec, (unknown)	22
11	Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial 2018 ·Endocrine Related Cancer ·Marianne Pavel, David J. Gross, Marta Benavent, Petros Perros, Raj Srirajaskanthan, Richard R.P. Warner, Matthew H. Kulke, Lowell Anthony, Pamela L. Kunz, Dieter Hörsch, Martin O. Weickert, Pablo Lapuerta, Wenjun Jiang, Kenneth Kassler-Taub, Suman Wason, (unknown), Douglas Fleming, Rocio García‐Carbonero	100
12	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors 2017 ·Neuroendocrinology ·Gregory Kaltsas, Martyn Caplin, Philippa Davies, Diego Ferone, Rocio García‐Carbonero, Simona Grozinsky‐Glasberg, Dieter Hörsch, Eva Tiensuu Janson, Réza Kianmanesh, Beata Kos‐Kudła, Marianne Pavel, Anja Rinke, Massimo Falconi, Wouter W. de Herder, (unknown)	99
13	Efficacy and Safety Results of Telotristat Ethyl in Patients With Carcinoid Syndrome During the Double-blind Treatment Period of the TELECAST Phase 3 Clinical Trial 2017 ·Pancreas ·Marianne Pavel, (unknown), Marta Benavent, M. Caplin, Petros Perros, Rajaventhan Srirajaskanthan, Juan W. Valle, Robert R. Warner, Michael Kulke, Lowell Anthony, Pamela L. Kunz, Dieter Hörsch, Kristian Berg, Pablo Lapuerta, (unknown), Phillip Banks, (unknown), Rocio García‐Carbonero	5
14	Integrated placebo-controlled safety analysis from clinical studies of telotristat ethyl for the treatment of carcinoid syndrome 2016 ·Annals of Oncology ·Matthew H. Kulke, Dieter Hörsch, Martyn Caplin, Lowell Anthony, Emily K. Bergsland, Kjell Öberg, Staffan Welin, Robert R. Warner, C. Lombard Bohas, Pamela L. Kunz, Enrique Grande, Juan W. Valle, Pablo Lapuerta, Phillip Banks, Shanna Jackson, Wenjun Jiang, (unknown), Marianne Pavel	5
15	Pancreatic neuroendocrine neoplasms. 2012 ·PubMed ·Dieter Hörsch, Tillmann Bert, J. Schrader, Merten Hommann, Daniel Kaemmerer, Alexander Petrovitch, John J. Zaknun, Richard P. Baum	10
16	Concomitant lung and gastroenteropancreatic neuroendocrine tumors and the value of gallium-68 PET/CT 2011 ·Cancer Imaging ·Daniel Kaemmerer, (unknown), Richard P. Baum, Dieter Hörsch, (unknown), Jörg Sänger, (unknown), Merten Hommann	6
17	Altered Signaling and Cell Cycle Regulation in Embryonal Stem Cells with a Disruption of the Gene for Phosphoinositide 3-Kinase Regulatory Subunit p85α 2003 ·Journal of Biological Chemistry ·(unknown), K Trümper, Heidi Trusheim, Kohjiro Ueki, C. Ronald Kahn, Lewis C. Cantley, David A. Fruman, Dieter Hörsch	34
18	Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in beta(INS-1)-cells 2002 ·Journal of Endocrinology ·(unknown), K Trümper, Dieter Hörsch	159
19	Integrative Mitogenic Role of Protein Kinase B/Akt in β‐Cells 2000 ·Annals of the New York Academy of Sciences ·K Trümper, (unknown), Heidi Trusheim, Rudolf Arnold, Burkhard Göke, Dieter Hörsch	55
20	Dual presence of chromogranin A-like immunoreactivity in a population of endocrine-like cells and in nerve fibers in the human anal canal 1991 ·Neuroscience Letters ·Eberhard Weihe, Dieter Hörsch, Lee E. Eiden, Wolfgang Hartschuh	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact